Peptide Reference

Melanotan-2: The Alpha-MSH Analog Behind Tanning, Appetite, and Libido Research

A focused reference on mechanism, research dosing conventions, regulatory status, and the safety concerns that set Melanotan-2 apart from more selective melanocortin peptides.

Last reviewed September 3, 2026 5 min read By Dave Belmonte, Founder
Melanotan-2 Alpha-MSH Melanocortin
Back to Expert Insights

What Is Melanotan-2 and How Does It Work

Melanotan-2 (MT-2) is a synthetic 7-amino-acid cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural hormone that regulates melanin production in the skin. It was developed at the University of Arizona in the 1980s as a candidate for sunless tanning and photoprotection research. Unlike more modern, receptor-selective melanocortin peptides, Melanotan-2 is a non-selective agonist - it activates multiple melanocortin receptor subtypes at once: MC1R (which drives eumelanin production and skin darkening), MC3R, MC4R (associated with appetite suppression and central sexual arousal pathways), and MC5R.

That lack of receptor selectivity is the mechanistic reason Melanotan-2 produces such a broad, and sometimes unpredictable, effect profile - tanning, appetite suppression, and increased libido or spontaneous erections can all show up in the same person, along with off-target effects like nausea and flushing. This is also the reason Melanotan-2 is not the same compound as PT-141 (bremelanotide): PT-141 was later derived from Melanotan-2 specifically by modifying it to act more selectively at MC4R, reducing the tanning and off-target activity while preserving the arousal-related effect. See the PT-141 (Bremelanotide) reference for that distinction in full.

Research Dosing

Dosing below reflects a mix of early human pharmacology research and long-standing research-community convention, not personal medical guidance and not a validated clinical dosing regimen. Melanotan-2 has never gone through an FDA dose-ranging program.

Phase Dose (commonly cited) Frequency Route
Loading / titration ~0.1–0.25mg, escalating to 0.5mg Daily, titrated over 1–3 weeks SubQ injection
Maintenance ~0.5–1mg 2–3× weekly SubQ injection

Context: An early phase-I human study by Dorr et al. used escalating doses from roughly 0.01 to 0.03 mg/kg body weight, dosed daily on a Monday-through-Friday schedule. Research-community loading/maintenance conventions descend from that early pharmacology work combined with years of informal use-pattern reporting, not a completed controlled dosing trial.

Regulatory Status

Melanotan-2 is not FDA-approved for tanning, appetite suppression, libido, or any other indication, and it is not currently listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as "Melanotan-2" or "MT-2" are marketed as research chemicals for laboratory research use only, not for human consumption. Multiple international regulators, including agencies in the UK and Australia, have separately issued public warnings over the years about Melanotan products sold illegally as tanning injections outside any regulated supply chain. Purchasing a product labeled "research use only" carries no assurance of purity, accurate dosing, or safety evaluation by any regulator.

Safety Considerations

Melanotan-2's safety profile is a meaningful part of why it has been superseded, for arousal-related research, by the more selective PT-141/bremelanotide. Commonly reported effects include nausea and facial flushing, particularly during dose escalation, along with injection site reactions and spontaneous erections in male users. More serious concerns are documented in the case-report literature: rapid darkening or growth of existing moles, new nevus (mole) formation, and rare reports connecting use to melanoma and to systemic toxicity including rhabdomyolysis. Because Melanotan-2 stimulates melanocyte activity broadly, changes in pigmented lesions can also make visual skin-cancer screening more difficult to interpret. Anyone with a personal or family history of atypical moles or melanoma should treat this as a significant consideration, and regular dermatological monitoring is a reasonable precaution for anyone considering it.

What Research Shows

The foundational human data on Melanotan-2 comes from an early pilot phase-I clinical study in a small number of male volunteers, which established the tanning, appetite-suppressing, and libido-related pharmacology, along with an initial dose range. Beyond that early pharmacology work, most of the available human evidence on Melanotan-2 specifically is observational or case-report level - documenting both intended effects and the mole/melanoma-related adverse events described above - rather than large randomized controlled trials. That is a meaningfully thinner evidence base than exists for its FDA-approved descendant compound, bremelanotide.

Research reference: Dorr RT et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sci. 1996;58(20):1777-1784. PMID: 8637402. View on PubMed

For the full breakdown of that pilot study and why Melanotan-2's evidence base stayed so much thinner than its FDA-approved descendant's, see Melanotan-2 Human Studies: What the 1996 Pilot Trial Showed.

Frequently Asked Questions

What is Melanotan-2?

Melanotan-2 (MT-2) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) studied for its ability to stimulate melanin production, suppress appetite, and increase libido. It works by non-selectively activating multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R) rather than targeting one pathway.

What's the typical research dose?

Research-community protocols commonly describe a loading phase of roughly 0.25-0.5mg daily, titrated upward from a lower starting dose to manage nausea, followed by a maintenance phase of roughly 0.5-1mg two to three times weekly. These figures come from community convention and early pharmacology research, not a completed FDA dose-ranging program.

Is Melanotan-2 the same as PT-141 (Bremelanotide)?

No. PT-141 (bremelanotide) was developed from Melanotan-2 by modifying it to act more selectively on the MC4R receptor associated with sexual arousal, reducing the tanning and off-target effects that come with Melanotan-2's broader receptor activity. Bremelanotide is FDA-approved as Vyleesi; Melanotan-2 is not approved for any use.

Is Melanotan-2 FDA-approved?

No. Melanotan-2 is not FDA-approved for tanning, appetite suppression, libido, or any other use. It is sold by suppliers as a research chemical for laboratory research use only, not for human consumption, and its purity and dosing accuracy are not regulated.

What are the main safety concerns with Melanotan-2?

The most commonly reported effects are nausea and facial flushing, especially during dose escalation. More serious documented concerns include changes in existing moles, new nevus formation, and case reports linking use to rapid mole changes and, in rare instances, melanoma and rhabdomyolysis. Anyone with a personal or family history of atypical moles or melanoma should be especially cautious.

Does Melanotan-2 need dermatological monitoring?

Because Melanotan-2 stimulates melanocyte activity and case reports document accelerated or atypical changes in existing moles, research-community sources and dermatologists commonly recommend baseline skin photography and regular monitoring of moles by a qualified professional for anyone considering it.

Disclaimer: This content is for informational purposes only. Melanotan-2 is a research compound not approved by the FDA for human use, and case reports have linked it to serious skin and pigmentation-related adverse effects. Always consult a qualified healthcare provider, and consider dermatological monitoring, before starting any peptide protocol. Nothing in this article constitutes medical advice.